The goal of this clinical research study is to find out if the combination of apalutamide (also known as ARN-509 or JNJ-56021927), abiraterone acetate, and prednisone can be given with either ipilimumab or cabazitaxel plus carboplatin to control metastatic CRPC. The safety and effectiveness of these drug combinations and their effect on the immune system will also be studied.